LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
31 funds hold it · Insiders trading both ways
Net buying: insiders sold $399K and bought $543K on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Financial period
Q3 2026
Earnings per share
$2.25 expected
Revenue
$1.43B expected
FY 2026 guidance
$4.70B to $5.10B
No comparable estimate
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $16.26est. $2.25 | +$14.01beat | $1.46Best. $1.43B+2.03% | +16.7%from $1.25B |
| Jun 30, 2026Reported Jul 30, 2026 | $1.84est. $2.14 | -14.21%miss | $1.29BCompany release | +66.9%from $773.7M |
| Mar 31, 2026Reported Apr 30, 2026 | $1.99est. $1.47 | +35.30%beat | $1.17BAlpha Vantage | +96.4%from $594.2M |
| Dec 31, 2025Reported Feb 12, 2026 | $1.25est. $1.50 | -16.50%miss | $1.10BAlpha Vantage | +84.9%from $593.2M |
| Sep 30, 2025Reported Oct 30, 2025 | $2.90est. $1.75 | +65.71%beat | $1.25BSEC filing | +149.3%from $500.9M |
| Jun 30, 2025Reported Jul 31, 2025 | $0.32est. $0.15 | +113.33%beat | $773.7MSEC filing | +17.3%from $659.8M |
| Mar 31, 2025Reported May 1, 2025 | -$0.01est. -$0.37 | +97.30%beat | $594.2MSEC filing | +20.2%from $494.3M |
| Dec 31, 2024Reported Feb 13, 2025 | $0.06est. -$0.14 | +142.86%beat | $593.2MAlpha Vantage | +34.9%from $439.7M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.10B | $1.17B | $1.29B | $1.46B |
| Cost of what it sold | $267.7M | $211.1M | $298.3M | $361.8M |
| Gross profit | $829.3M | $956.1M | $992.7M | $1.10B |
| What it spent | ||||
| Research and development | $372.2M | $364.9M | $413.1M | $408.5M |
| Sales and admin | $325.4M | $322.6M | $347.9M | $342.0M |
| Total operating expenses | $697.6M | $687.4M | $761.2M | $750.5M |
| What was left | ||||
| Operating profit | $131.7M | $268.6M | $231.4M | $345.8M |
| Interest on debt | $129.3M | $69.3M | $82.1M | $84.4M |
| Profit before tax | $161.1M | $221.7M | $177.8M | $295.8M |
| Tax | -$25.3M | -$15.7M | $13.3M | -$1.87B |
| Net profit | $186.4M | $206.0M | $164.5M | $2.17B |
| EBITDA | $304.0M | $304.5M | $245.1M | $394.7M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
BullishNov 10Weekly Recap: $1 billion buyback authorized and Truist downgrades to Hold
NeutralNov 9Alnylam Pharmaceuticals (ALNY) Faces A Valuation Test After Fresh AMVUTTRA Data
Leans bearishNov 8We Believe Alnylam Pharmaceuticals' (NASDAQ:ALNY) Earnings Are A Poor Guide For Its Profitability
BearishNov 7Alnylam Pharmaceuticals stock hits 52-week low at $155.22
BearishNov 6Why Alnylam Pharmaceuticals Bears Were Right Before A 65% Drop
Leans bearishNov 6Alnylam Pharmaceuticals announces $1 billion stock repurchase program and executive departure
Leans bearishNov 5Form 8K Alnylam Pharmaceuticals Inc For: 5 November By Investing.com
NeutralNov 536 macro signals shaping ALNY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
